Rachel Cusatis1,2, Joanna Balza3, Zachary Uttke4, Vishwajit Kode5, Elizabeth Suelzer6, Bronwen E Shaw7, Kathryn E Flynn7,5. 1. Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA. rcusatis@mcw.edu. 2. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. rcusatis@mcw.edu. 3. Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA. 4. National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 5. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 6. Medical College of Wisconsin Libraries, Milwaukee, WI, USA. 7. Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
PURPOSE: Cognitive dysfunction is a known complication following cellular therapies (CT), which can be assessed through performance based and patient-reported measures. We performed a systematic scoping review to assess self-reported cognitive function measures used among adult CT patients and describe long-term results, including associations with clinical outcomes. METHODS: Library databases were searched from inception to February 2020 according to PRISMA guidelines. Additional studies were identified through reference lists and trial protocols. Two members of the research team screened titles and abstracts and resolved discrepancies. Articles that met eligibility criteria continued to full-text review, with 25% double screening. Articles were removed if they (1) were not original research, peer-reviewed articles; (2) were the wrong disease, age, or treatment-specific patient population; (3) did not use patient-reported outcomes; (4) did not separately report cognitive function outcomes. RESULTS: Of the1952 articles, 56 were included. Twenty-one patient-reported measures of cognitive function were used; most frequently the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), which includes a two-item cognitive function subscale (57%; n = 32). Thirteen studies collected performance-based and self-reported measures and of those (n = 6) who assessed associations found moderate correlations (range r = .13-.58). Longitudinal patterns showed declines in cognitive function soon after treatment (< 1 month) returning to baseline at 1 year. Cognitive function was often associated with other quality of life measures, chiefly depression (n = 5). CONCLUSIONS: EORTC-QLQ-C30 is the most commonly used to measure, though there remain numerous measures used, including several measures with little previous validation and investigator developed items.
PURPOSE: Cognitive dysfunction is a known complication following cellular therapies (CT), which can be assessed through performance based and patient-reported measures. We performed a systematic scoping review to assess self-reported cognitive function measures used among adult CT patients and describe long-term results, including associations with clinical outcomes. METHODS: Library databases were searched from inception to February 2020 according to PRISMA guidelines. Additional studies were identified through reference lists and trial protocols. Two members of the research team screened titles and abstracts and resolved discrepancies. Articles that met eligibility criteria continued to full-text review, with 25% double screening. Articles were removed if they (1) were not original research, peer-reviewed articles; (2) were the wrong disease, age, or treatment-specific patient population; (3) did not use patient-reported outcomes; (4) did not separately report cognitive function outcomes. RESULTS: Of the1952 articles, 56 were included. Twenty-one patient-reported measures of cognitive function were used; most frequently the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), which includes a two-item cognitive function subscale (57%; n = 32). Thirteen studies collected performance-based and self-reported measures and of those (n = 6) who assessed associations found moderate correlations (range r = .13-.58). Longitudinal patterns showed declines in cognitive function soon after treatment (< 1 month) returning to baseline at 1 year. Cognitive function was often associated with other quality of life measures, chiefly depression (n = 5). CONCLUSIONS: EORTC-QLQ-C30 is the most commonly used to measure, though there remain numerous measures used, including several measures with little previous validation and investigator developed items.
Authors: Boaz Y Saffer; Shawnda C Lanting; Michael S Koehle; E David Klonsky; Grant L Iverson Journal: Psychiatry Res Date: 2015-01-08 Impact factor: 3.222
Authors: Amanda D Hutchinson; Jessica R Hosking; Ganessan Kichenadasse; Julie K Mattiske; Carlene Wilson Journal: Cancer Treat Rev Date: 2012-06-02 Impact factor: 12.111
Authors: Richard T Maziarz; Edmund K Waller; Ulrich Jaeger; Isabelle Fleury; Joseph McGuirk; Harald Holte; Samantha Jaglowski; Stephen J Schuster; Michael R Bishop; Jason R Westin; Stephan Mielke; Takanori Teshima; Veronika Bachanova; Stephen R Foley; Peter Borchmann; Gilles A Salles; Jie Zhang; Ranjan Tiwari; Lida B Pacaud; Qiufei Ma; Constantine S Tam Journal: Blood Adv Date: 2020-02-25
Authors: Sofia F Garcia; David Cella; Steven B Clauser; Kathryn E Flynn; Thomas Lad; Jin-Shei Lai; Bryce B Reeve; Ashley Wilder Smith; Arthur A Stone; Kevin Weinfurt Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu Journal: Biol Blood Marrow Transplant Date: 2018-12-25 Impact factor: 5.742